{"result": "(\"entity\"<|>ALENDRONATO<|>PERSON<|>Alendronato is a bisphosphonate medication used to treat osteoporosis, effective in reducing bone resorption and increasing bone mineral density.)\n##\n(\"entity\"<|>RIZEDRONATO<|>PERSON<|>Risedronato is a second-generation bisphosphonate used for the treatment of osteoporosis, known for its effectiveness in reducing fractures.)\n##\n(\"entity\"<|>DENOSUMAB<|>PERSON<|>Denosumab is a fully human monoclonal antibody that inhibits RANKL, reducing bone resorption and increasing bone mineral density in osteoporosis treatment.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a medical condition characterized by weakened bones, increasing the risk of fractures, particularly in postmenopausal women.)\n##\n(\"entity\"<|>EASTELL R<|>PERSON<|>Eastell R is an author of clinical guidelines on the pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>ROSEN CJ<|>PERSON<|>Rosen CJ is a co-author of clinical guidelines on osteoporosis management and has contributed to research in this field.)\n##\n(\"entity\"<|>BLACK DM<|>PERSON<|>Black DM is a researcher involved in the study of osteoporosis and its treatment options.)\n##\n(\"entity\"<|>MELMED S<|>PERSON<|>Melmed S is an author of a textbook on endocrinology that includes information on osteoporosis treatment.)\n##\n(\"entity\"<|>TAMOXIFENO<|>PERSON<|>Tamoxifen is a selective estrogen receptor modulator used in breast cancer treatment and has effects on bone health.)\n##\n(\"entity\"<|>RALOXIFENO<|>PERSON<|>Raloxifene is a selective estrogen receptor modulator that reduces the risk of vertebral fractures in postmenopausal women.)\n##\n(\"relationship\"<|>ALENDRONATO<|>OSTEOPOROSIS<|>Alendronato is used to treat osteoporosis by reducing bone resorption and increasing bone mineral density<|>9)\n##\n(\"relationship\"<|>RIZEDRONATO<|>OSTEOPOROSIS<|>Rizedronato is effective in treating osteoporosis and reducing the risk of fractures<|>9)\n##\n(\"relationship\"<|>DENOSUMAB<|>OSTEOPOROSIS<|>Denosumab is used to treat osteoporosis by inhibiting RANKL, thus reducing bone resorption<|>9)\n##\n(\"relationship\"<|>EASTELL R<|>OSTEOPOROSIS<|>Eastell R contributed to clinical guidelines for the management of osteoporosis<|>7)\n##\n(\"relationship\"<|>ROSEN CJ<|>OSTEOPOROSIS<|>Rosen CJ is involved in the development of clinical guidelines for osteoporosis treatment<|>7)\n##\n(\"relationship\"<|>BLACK DM<|>OSTEOPOROSIS<|>Black DM has conducted research related to osteoporosis and its treatment<|>7)\n##\n(\"relationship\"<|>MELMED S<|>OSTEOPOROSIS<|>Melmed S authored a textbook that discusses osteoporosis management<|>6)\n##\n(\"relationship\"<|>TAMOXIFENO<|>OSTEOPOROSIS<|>Tamoxifen has implications for bone health and is used in breast cancer treatment<|>5)\n##\n(\"relationship\"<|>RALOXIFENO<|>OSTEOPOROSIS<|>Raloxifene is used to reduce the risk of fractures in postmenopausal women with osteoporosis<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: los fármacos más usados en el tratamiento de la osteoporosis. Señale la respuesta cierta:\n\nA. El alendronato semanal ocasiona esofagitis erosiva con la misma frecuencia que su presentación diaria.\nB. El alendronato no tiene indicación para utilizarse en la osteoporosis del varón.\nC. El efecto beneficioso del alendronato sobre la masa ósea desaparece a los 3 meses de suspender el tratamiento.\nD. El ibandronato tiene un peor resultado sobre las fracturas no vertebrales que el alendronato.\n\n### COMENTARIO\n\nLos tratamientos antirresortivos inhiben la resorción ósea mediante supresión de la actividad osteoclástica. Ralentizar el ciclo de remodelación permite que la formación ósea se equilibre con la resorción, aumentando de este modo la mineralización de la matriz estabilizando la microestructura trabecular. Los antirresortivos incrementan la DMO y disminuyen el riesgo de fractura, pero su eficacia varía.\n\nLos bisfosfonatos son los antirresortivos más utilizados y a menudo se consideran el tratamiento de elección de la osteoporosis posmenopáusica grave y también en la osteoporosis del varón. El alendronato y el risedronato son dos bisfosfonatos nitrogenados de segunda generación, son efectivos para reducir la resorción ósea y aumentar la DMO. En mujeres posmenopáusicas con osteoporosis confirmada, el alendronato y el risedronato disminuyeron casi un 50% las fracturas vertebrales, de cadera y no vertebrales, especialmente durante el primer año de tratamiento.\n\nIgual que con otros antirresortivos, el aumento de la DMO es responsable de una pequeña proporción de su eficacia antifractura. Por tanto, las evaluaciones de la DMO de seguimiento pueden subestimar considerablemente la disminución del riesgo de fractura.\n\nEstudios clínicos recientes han mostrado que estos fármacos pueden administrarse de manera segura durante 5 años como mínimo sin efecto adverso en la fortaleza ósea. Es más,\n\n### Referencias:\n- Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1595-622.\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. Rosen CJ, Schmader KE, eds. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n- Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Rosen CJ, Schmader KE, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n\n## 21. En mujeres posmenopáusicas con osteoporosis: (señale la opción cierta)\n\nA. El raloxifeno reduce el riesgo de fracturas vertebrales y de cadera.\nB. El tratamiento con denosumab reduce los marcadores de resorción ósea.\nC. La calcitonina ha demostrado reducción de fracturas de cadera.\nD. El ranelato de estroncio reduce eventos cardiovasculares.\n\n### COMENTARIO\n\nEl denosumab es un anticuerpo monoclonal completamente humano contra el RANKL, el principal factor diferenciador del osteoclasto. Este anticuerpo inhibe la formación de osteoclastos, disminuye la resorción ósea, aumenta la DMO y baja el riesgo de fractura.\n\nA diferencia de los bisfosfonatos, el denosumab no permanece en el esqueleto y por eso es necesario administrarlo cada 6 meses para mantener su eficacia. De hecho, la interrupción del denosumab puede causar un aumento de rebote de la resorción ósea.\n\nUno de los estudios clínicos con 60 mg de denosumab cada 6 meses demostró que después de 3 años el denosumab mejoró la DMO en la columna vertebral y en la cadera comparado con el placebo. Además, los marcadores bioquímicos de recambio óseo disminuyeron significativamente.\n\nLos moduladores selectivos del receptor de estrógeno, como el tamoxifeno y el raloxifeno bloquean las acciones del estrógeno en la mama, pero actúan como agonistas de\n---\nMETABOLISMO FOSFOCÁLCICO, TUMORES NEUROENDOCRINOS Y MEN 7\n\nestrógeno en el hueso. Ambos fármacos se han asociado a una reducción de cáncer de mama. La concentr\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}